Contraceptive Drugs Market Size, Share, and Trends 2024 to 2034

Contraceptive Drugs Market Size and Growth 2024 to 2033

The global contraceptive drugs market size was valued at USD 16.94 billion in 2023 and it is expected to hit around USD 30.06 billion by 2033, poised to grow at a CAGR of 5.9% from 2024 to 2033.

Contraceptive Drugs Market Key Takeaways

• North America led the global market with the highest market share of 40.14% in 2023.
• Asia Pacific region is estimated to expand the fastest CAGR between 2024 and 2033.
• By Product, the oral contraceptive drugs segment has held the largest market share in 2023.
• By Product, the vaginal ring segment is expected to expand at the fastest CAGR over the projected period.
• By Distribution Channel, the retail pharmacy segment captured the biggest revenue share in 2023.

U.S. Contraceptive Drugs Market Size and Growth 2024 to 2033

The U.S. contraceptive drugs market size was estimated at USD 4.77 billion in 2023 and is predicted to be worth around USD 8.92 billion by 2033, at a CAGR of 6.5% from 2024 to 2033.

North America dominated the contraceptive drugs market in 2023. The growth of contraceptive drugs market in North America region is being driven by growing awareness about contraceptive pills among patients. According to Centers for Disease Control estimates, 14% of women aged 15 to 49 will be using contraceptive drugs in 2020. In addition, different strategies adopted by market players are also driving the growth of North America contraceptive drugs market. According to data published by the Bill & Melinda Gates Foundation in 2022, the foundation plans to invest $280 million per year from 2024 to 2033 in developing innovative and latest contraceptive technologies, supporting family planning programs that reflect local community preferences.

Asia-Pacific, on the other hand, is expected to develop at the fastest rate during the forecast period. The Asia-Pacific contraceptive drugs market growth is attributed to the growing reimbursement policies. In addition, the rising childbearing population is also driving the growth of contraceptive drugs market in Asia-Pacific region. As per the report released by the United Nations Department of Economic and Social Affairs, the population was over 163 million in 2019. More than 56% of women in this category utilize contraception. As a result, the expansion of contraceptive drugs market in this region is expected in near future.

Contraceptive Drugs Market Growth Factors

The rising number of unwanted births is a primary factor driving demand for contraceptive drugs, resulting in global contraceptive drugs market expansion. According to a March 2021 estimate from the United Nations Population Fund, the number of unplanned pregnancies in 115 low- and middle-income nations was 1.4 million in 2020. As a result of these figures, the global demand for contraceptive tablets is increasing, leading to the growth of the global contraceptive drugs market.

The key driver enhancing the global contraceptive drugs market’s growth is the increased focus of leading industry players and healthcare organizations on promoting awareness through public programs to expand access to contraceptive drug options. For example, HRA Pharma, a European pharmaceutical firm, established cooperation with Ibis Reproductive Health, a non-profit organization dedicated to improving women’s reproductive autonomy, in January 2017 to launch over-the-counter medications in the U.S.

During the projection period, the growth of the global contraceptive drugs market is likely to be driven by the approval, development, and commercialization of novel and long-lasting techniques. Agile Therapeutics, for example, created Twirla, a hormonal patch that was released in the 4^th quarter of 2020 in the U.S. Teenagers’ desire for contraception has increased as a result of the introduction of low cost and generic medications and technologies. As a result, the global contraceptive drugs market growth is expected in coming years.

The global contraceptive drugs market’s rivalry is expected to heat up a several major competitors focus on expanding their product portfolios through collaborations and acquisitions. The contraceptive drugs market is likely to provide new market players as well as established market leaders with several chances. Furthermore, joint ventures, mergers, and partnerships aid in boosting the presence of companies in the global contraceptive drugs market, thus assisting in improving the contraceptive drugs market’s growth rate.

Contraceptive Drugs Market Scope

Product Insights

The oral contraceptive drugs segment has the largest revenue share in 2023. The oral contraceptive drugs demand and acceptance are gradually increasing, particularly in developing markets. This is owing to the clinical advantages of oral contraceptive drugs over other traditional techniques, as well as the reduced cost of these medications compared to other modern contraceptive drugs options. The number of women of reproductive age who use birth control tablets has climbed from roughly 97 million in 1994 to 151 million in 2019.

The vaginal ring segment is expected to reach remarkable growth from 2024 to 2033. The factors such as long product life cycle as well as cost effectiveness are driving the growth of the segment. The introduction of new products and the ease of use of vaginal rings are projected to boost demand for these birth control techniques. Annovera, a reusable silicone ring that protects against unplanned pregnancy for up to a year, received Food and Drug Administration approval and five-year market monopoly as a novel chemical entity in September 2018 and will be commercially introduced in the 1^st quarter of 2020.

Distribution Channel Insights

The retail pharmacy segment accounted largest revenue share in 2023. This is attributed to rising demand for contraceptive pills among the general public as well as increased awareness of various contraceptive drugs options. Birth control tablets are sold over the counter in various nations. As a result, customers are increasingly turning to retail pharmacies to obtain birth control tablets. Furthermore, favorable regulations have contributed to the expansion of the segment.

The online distribution channel segment is projected to grow at fastest rate during the forecast period. The increased usage of over-the-counter solutions, coupled with numerous online discounts and offers to entice clients, is ascribed to the larger growth of online channels.

Contraceptive Drugs Market Recent Developments

• Abbvie Inc. finalized the acquisition of Allergen in May 2020, bolstering its position as a strong leader in a number of therapeutic areas.
• The Food and Drug Administration approved NEXSTELLIS for the prevention of pregnancy in April 2021, according to Mayne Pharma. NEXSTELLIS is the first and only contraceptive drug that contains E4, a naturally occurring estrogen that is now synthesized from a plant source and has a unique mode of action. 
• Sayana Press, for example, is the first injectable contraception for women available in the UK, due to Pfizer Inc. A study testing levonorgestrel and ethinyl estradiol as potential oral contraceptives is also underway at the company.
•  Nurx and TherapeuticsMD Inc., an online company specializing in women’s health, signed an agreement in July 2020 to expand Annovera’s availability.
•  Bayer AG declared the completion of its acquisition of KaNDy Therapeutics Ltd. in September 2020, with the goal of improving its drug development portfolio in the women’s healthcare segment.
•  Afaxys Inc. and TherapeuticsMD Inc., announced a deal in February 2020 to expand Annovera’s availability in the U.S.’s public healthcare system.
•  Merck & Co, Inc. provides contraceptive tablets, intrauterine devices, vaginal rings, and subdermal implants. Desogen, Cyclessa, Implanon, NuvaRing, and Nexplanon are all popular products. 

Contraceptive Drugs Market Companies

• Church & Dwight Co., Inc.
• Reckitt Benckiser Group Plc
• Veru, Inc.
• Organon Group of Companies
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
• The Cooper Companies, Inc.
• Mayer Laboratories, Inc.
• Agile Therapeutics
• TherapeuticsmMD, Inc.
• Bayer Ag
• Afaxys, Inc.
• Mithra Pharmaceuticals
• Abbvie

 Segments Covered in the Report

By Product

• Oral
• Pills
• Intrauterine Devices (IUD)
• Hormonal IUD
• Nonhormonal IUD
• Condoms
• Male Condoms
• Female Condoms
• Vaginal Ring
• Subdermal Implants
• Injectable
• Others

 By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Clinics
• Online Channel
• Public Channel & NGOs
• Others

By Age Group

• 15–24 years
• 25–34 years
• 35–44 years
• Above 44 years

 By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa